New autoantibody detection technologies yield novel insights into autoimmune disease

Purpose of reviewThe purpose of this review is to highlight recent progress in autoantibody detection technologies and describe how these methods are providing novel information and insights into autoimmune disorders. Recent findingsIn recent years, alternative methods such as comprehensive phage display, fluid-phase immunoassays, and antigen microarrays have been developed for autoantigen discovery and profiling autoantibody responses. Compared with classic approaches such as Western blot and ELISA, these methods show improved diagnostic performance, the ability to measure antibody responses to multiple targets, and/or allow more quantitative analyses. Specific notable findings include uncovering previously unrecognized autoantigens, the improved classification of patient clinical phenotypes, and the discovery of pathogenic autoantibodies promoting disease. SummaryAdvances in immunoassay technologies offer many opportunities for understanding the relationship between autoantibody detection and the myriad complex, clinical phenotypes characteristic of most autoimmune diseases. Further simplification and standardization of these technologies may allow routine integration into clinical practice with improved diagnostic and therapeutic outcomes.

[1]  B. L. Han,et al.  Antibody-profiling technologies for studying humoral responses to infectious agents , 2010, Expert review of vaccines.

[2]  G. Eisenbarth,et al.  A Common Nonsynonymous Single Nucleotide Polymorphism in the SLC30A8 Gene Determines ZnT8 Autoantibody Specificity in Type 1 Diabetes , 2008, Diabetes.

[3]  Joshua LaBaer,et al.  Serological autoantibody profiling of type 1 diabetes by protein arrays. , 2013, Journal of proteomics.

[4]  Chandra Mohan,et al.  Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. , 2005, The Journal of clinical investigation.

[5]  R. Hohlfeld,et al.  Cellular immune mechanisms in inflammatory myopathies. , 1997, Current opinion in rheumatology.

[6]  Joshua LaBaer,et al.  Detection of Multiple Autoantibodies in Patients with Ankylosing Spondylitis Using Nucleic Acid Programmable Protein Arrays* , 2010, Molecular & Cellular Proteomics.

[7]  Uri Laserson,et al.  Autoantigen discovery with a synthetic human peptidome. , 2011, Nature biotechnology.

[8]  T. Dörner,et al.  Immunopathogenic mechanisms of systemic autoimmune disease , 2013, The Lancet.

[9]  Smita Y. Patel,et al.  Adult-onset immunodeficiency in Thailand and Taiwan. , 2012, The New England journal of medicine.

[10]  J. Tschopp,et al.  Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.

[11]  B. Engelen,et al.  Autoantibodies to cytosolic 5′‐nucleotidase 1A in inclusion body myositis , 2013, Annals of neurology.

[12]  L. Devy,et al.  Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. , 2005, The Journal of clinical investigation.

[13]  Alexander R. Abbas,et al.  Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[14]  I. Ben-Dov,et al.  Autoimmune pulmonary alveolar proteinosis: clinical course and diagnostic criteria. , 2014, Autoimmunity reviews.

[15]  M. Petri,et al.  Two Major Autoantibody Clusters in Systemic Lupus Erythematosus , 2012, PloS one.

[16]  S. Holland,et al.  Anti–GM-CSF Autoantibodies in Patients with Cryptococcal Meningitis , 2013, The Journal of Immunology.

[17]  Daniele Focosi,et al.  A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. , 2010, The New England journal of medicine.

[18]  R. Jacobs,et al.  Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-gamma autoantibody. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  G. Illei,et al.  Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjögren's syndrome , 2009, Autoimmunity.

[20]  N. Olsen,et al.  Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes , 2006, Clinical and experimental immunology.

[21]  Hanno Steen,et al.  Cytosolic 5′‐nucleotidase 1A autoimmunity in sporadic inclusion body myositis , 2013, Annals of neurology.

[22]  Steven A. Greenberg,et al.  Autoantibodies against a 43 KDa Muscle Protein in Inclusion Body Myositis , 2011, PloS one.

[23]  Paul J Utz,et al.  Technology Insight: can autoantibody profiling improve clinical practice? , 2007, Nature Clinical Practice Rheumatology.

[24]  C. Raoul,et al.  Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis , 2014, Multiple sclerosis.

[25]  F. Miller,et al.  Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis , 2014, BMC Musculoskeletal Disorders.

[26]  K. Kalunian,et al.  Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study , 2013, Arthritis and rheumatism.

[27]  Mark S. Anderson,et al.  BPIFB1 Is a Lung-Specific Autoantigen Associated with Interstitial Lung Disease , 2013, Science Translational Medicine.

[28]  Bonnie Bruce,et al.  Antigen microarray profiling of autoantibodies in rheumatoid arthritis. , 2005, Arthritis and rheumatism.

[29]  M. Petri,et al.  A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[30]  L. Rönnblom,et al.  Interferon-α induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. , 2013, Arthritis and rheumatism.

[31]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[32]  S. Holland,et al.  Anti-Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies Are a Risk Factor for Central Nervous System Infection by Cryptococcus gattii in Otherwise Immunocompetent Patients , 2014, mBio.

[33]  Joshua LaBaer,et al.  Circulating and synovial antibody profiling of juvenile arthritis patients by nucleic acid programmable protein arrays , 2012, Arthritis Research & Therapy.

[34]  S. Holland,et al.  Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. , 2012, Blood.

[35]  P. Brown,et al.  Autoantigen microarrays for multiplex characterization of autoantibody responses , 2002, Nature Medicine.

[36]  Göran Hallmans,et al.  Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden , 2011, Arthritis Research & Therapy.

[37]  Yuchen Jiao,et al.  Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer , 2014, Science.

[38]  R. Jonsson,et al.  Autoantibodies present before symptom onset in primary Sjögren syndrome. , 2013, JAMA.

[39]  J. Wenzlau,et al.  Novel Diabetes Autoantibodies and Prediction of Type 1 Diabetes , 2013, Current Diabetes Reports.

[40]  W. Robinson,et al.  Human peptidome display , 2011, Nature Biotechnology.

[41]  M. Iadarola,et al.  Searching for biomarkers: humoral response profiling with luciferase immunoprecipitation systems , 2011, Expert review of proteomics.

[42]  G. Church,et al.  PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. , 2013, Journal of autoimmunity.

[43]  Mark S. Anderson,et al.  Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. , 2013, The Journal of clinical investigation.

[44]  Bernhard Hemmer,et al.  Potassium channel KIR4.1 as an immune target in multiple sclerosis. , 2012, The New England journal of medicine.

[45]  G. Eisenbarth,et al.  Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. , 2007, Clinical immunology.